Abstract
Cytokine-targeted biologics have revolutionized the management of moderate-to-severe psoriasis; however, all available therapies have failed a growing number of patients. Mesenchymal stromal cells (MSCs), with their immunomodulatory properties, offer a novel therapeutic option. Here, we report the cases of three adult female patients with long-standing, severe plaque psoriasis who were refractory to multiple biologic therapies, and were consequently treated with two intravenous infusions of allogeneic umbilical cord-derived MSCs (UC-MSCs; 1.96 – 3.00 × 106 cells/kg) 1 week (W) apart. Two patients received UC-MSCs as monotherapy; one received them alongside etanercept. Upon relapse, two patients resumed their last failed biologic at W9, while one switched to a new biologic at W24. UC-MSCs were well-tolerated and yielded variable clinical benefits. The best responder to MSCs experienced an 87% reduction in the Psoriasis Area and Severity Index (PASI 87) by W4. Two patients showed improved responses to previously failed biologics (absolute PASI of 0–2), sustained for over 2 years following reinitiation. Multi-parameter flow cytometry revealed increased frequencies of CD4+ and CD8+ skin-homing (CLA+CD103−) and skin-recirculating (CLA+CD103+) memory T cells, CD25HiCD127LoFoxP3+ regulatory T cells, and non-classical (CD14LoCD16+) monocytes, associated with clinical improvements. These findings suggest that UC-MSCs may potentially provide direct benefits for biologic-refractory psoriasis and restore responsiveness to previously ineffective biologics, possibly by resetting the immune response. Further investigation in larger cohorts is warranted.
Introduction
Psoriasis is a common, debilitating, and life-shortening inflammatory skin disease that affects more than 60 million people worldwide. It presents as red (gray on darker skin), heavily scaled plaques that can appear on any skin surface, severely impacting physical and mental health. The disease usually starts before the age of 30 (), and is linked to systemic inflammation, including arthritis, heart disease, diabetes, and depression, making it a serious systemic condition. It is caused by gene–environment interactions and a complex interplay of innate and adaptive immunity, resulting in a perpetual inflammatory loop underpinned by the interleukin (IL)-23/type 17 T cell (Th17) axis (). Biologics that target cytokine pathways have transformed the management of psoriasis, but none are curative (). Furthermore, all available classes of biologic therapy have failed an increasing number of patients, i.e., tumor necrosis factor (TNF), IL - 17, IL - 23p40, and IL - 23p19 inhibitors (, ). Mesenchymal stromal cells (MSCs) are a heterogeneous population of multipotent stem cells with immunomodulatory properties and low immunogenicity, which renders them an attractive form of cell therapy for immune-mediated inflammatory diseases (IMIDs) (–). In recent years, case series and small clinical trials have reported on the safety and efficacy of MSCs in patients with psoriasis (–). However, to date, studies on the use of MSCs in the difficult-to-treat, multiple-biologic-failure psoriasis population are sparse (, , ). We report on the safety, efficacy, and immunomodulatory capacity of systemic allogeneic umbilical cord-derived MSCs (UC-MSCs) in three adults with severe, biologic-refractory psoriasis over 2 years of follow-up.
Case descriptions
Patient 1
A 46-year-old white European woman with plaque psoriasis for 25 years presented with a severe flare of the disease while on an etanercept biosimilar (Benepali, anti-TNF) (Figure 1). Benepali was initiated following an infusion reaction to infliximab. She had secondary failure to five biologics across four classes—secukinumab (anti-IL-17A; ± methotrexate), adalimumab (anti-TNF; ± methotrexate), guselkumab (anti-IL-23p19), risankizumab (anti-IL23p19), and infliximab (anti-TNF)—and had primary failure to ixekizumab (anti-IL-17A). Comorbidities included psoriatic arthritis, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), anxiety, and depression. Examination revealed large, widespread, inflammatory plaques involving high-impact sites and nail disease. Her baseline disease severity scores included Psoriasis Area Severity Index (PASI), 37.6; Dermatology Life Quality Index (DLQI), 27; Patient Health Questionnaire-9 (PHQ9), 23; Generalized Anxiety Disorder 7-item (GAD7), 17; and tender joint count (TJC), 13.
Figure 1
In light of her deteriorating status and absence of clinical improvement with etanercept biosimilar alone for 9 weeks, she received two intravenous infusions of allogeneic UC-MSCs, 2.57 × 106 cells/kg/infusion (weight 89 kg; total cells per infusion: 229 × 106) 1 week (W) apart, as an adjuvant therapy—a salvage intervention rather than part of a combination therapy planned upfront. Post-MSC infusions, her laboratory and vital signs remained stable. No serious adverse events occurred, although mild cannulation-site thrombophlebitis resolved with conservative management.
By W2, the PASI had reduced to 23 (PASI39), the DLQI had reduced to 10 (−17), with improvements in itch, TJC (−4), PHQ9 (−14), and GAD7 (−12). At W10, the PASI was at its lowest at 21.8 (PASI42). At W24, the PASI had increased to 30.7 despite the continuation of etanercept. She switched to a new biologic—bimekizumab—achieving an absolute PASI8 at W62 (PASI79 from baseline).
Patient 2
A 45-year-old South Asian woman with small-plaque and follicular psoriasis for 25 years presented with breakthrough flares of psoriasis at W5 on guselkumab 2.5 years into treatment (Figure 2). She had secondary failure to four biologics across three classes: adalimumab and etanercept biosimilar; ustekinumab (anti-IL-23p40); and secukinumab. Her baseline PASI was 13.8, her DLQI was 15, her PHQ9 was 9, and her GAD7 was 3. She received UC-MSCs as monotherapy, 3.00 × 106 cells/kg/infusion (weight 76.3 kg; total cells per infusion: 229 × 106) 1 week (W) apart, after an 8-week guselkumab washout period. Mild, transient nausea and tachycardia (112 bpm) occurred during infusion, which resolved spontaneously. Laboratory parameters remained stable post-MSCs.
Figure 2
By Day 3, itching was reduced by 90%. At W1, the PASI had decreased to 8.2 (PASI41) and the DLQI had decreased to 12 (−3), and by W4, the PASI and DLQI had reduced to 1.8 (PASI87) and 8 (−7), respectively. This significant improvement in PASI scores was transient, and psoriasis relapsed at W9 post-MSCs, with an absolute PASI of 16.9 and a DLQI of 20; her last ineffective biologic, guselkumab, was reinitiated at a loading dose. Within 4 weeks, the PASI improved by 50% and the DLQI decreased from 20 to 5; she maintained an absolute PASI <2 for over 2 years—her best response to date.
Patient 3
A 47-year-old Chinese woman with long-standing large-plaque psoriasis (Figure 3) with vulvar involvement had NAFLD and tested positive for hepatitis B core antibody (she was receiving entecavir treatment). She had secondary failure to five biologics across four classes—adalimumab ± methotrexate, ustekinumab, secukinumab, risankizumab, and brodalumab—with breakthrough flares at W3–4 on bimekizumab (anti-IL-17A/F). Her baseline PASI score was 22.8, with a DLQI of 20.
Figure 3
She received UC-MSCs as monotherapy, 1.96 × 106 cells/kg/infusion (weight 77 kg; total cells per infusion: 151 × 106) 1 week (W) apart, after an 8-week bimekizumab washout period. Transient infusion headaches resolved spontaneously. Vital signs and laboratory parameters remained stable post-treatment. There was no direct benefit from the UC-MSCs (the PASI had reduced to 16.9 and the DLQI had reduced to 5 at W2), followed by a flare (the absolute PASI was 29.1, and the DLQI was 17) post-sunburn during a holiday in Spain. Bimekizumab was restarted at W10, leading to an absolute PASI of 1.2 at W18 and 0 at W80 post-MSC (W70 post-bimekizumab reinitiation).
We performed a biomarker assay that predicts clinical response to MSCs for the three patients with psoriasis, which was previously validated in patients with graft-versus-host disease and Crohn disease (, ). This assay is based on the observation that MSCs, upon intravenous infusion, undergo apoptosis induced by recipient cytotoxic cells, and measures the molecular and functional profiles of recipient monocytes exposed to apoptotic MSCs (ApoMSCs). Patient 1 exhibited a borderline positive cytotoxic killing capacity at 11% ApoMSCs; Patient 2 was highly positive at 30%. Patient 3 was intermediate at 18% (Supplementary Figure 4).
Multi-parameter flow cytometry of all three patients revealed distinct immune profiles at baseline. Specifically, Patients 1 and 3, who had large-plaque psoriasis, had higher frequencies of IL - 17A-producing CD4+ and CD8+ T cells compared to Patient 2, who had small-plaque, follicular psoriasis and had a higher frequency of interferon (IFN)-γ-producing counterparts (Supplementary Figure 6). Interestingly, this observation was also reflected in IL-17A- and IL-22-producing skin recirculating CD4+ and CD8+ T cells, with a similar pattern observed in B cells and type 1 conventional dendritic cells (cDC1). Some patients showed similar trends in some cell subsets of the lymphoid (Figure 4, Supplementary Figure 5) and myeloid compartments (Supplementary Figure 7) following UC-MSC therapy: increased frequencies of CD4+ and CD8+ skin-recirculating (CLA+CD103+) memory T cells (, ) and CD25HiCD127LoFoxP3+ regulatory T cells (Supplementary Figure 8), but decreased frequencies of intermediate (CD14+CD16+) monocytes, associated with clinical improvements. Variation between individuals was noted, and the observations above are based on descriptive rather than statistical analysis due to the small sample size.
Figure 4
Discussion
MSCs have emerged as a promising therapeutic avenue for patients with severe plaque psoriasis,; however, their role in biologic-refractory cases remains largely unexplored (, –). To our knowledge, this is the first report describing the use of MSCs as rescue therapy in patients with severe, multiple-biologic-resistant psoriasis, demonstrating an acceptable safety profile and suggesting potential clinical benefits, including a sustained (>2 years), regained response to a previously failed biologic in three selected cases.
Our data suggest that UC-MSCs are well tolerated and safe for at least the duration of follow-up (>2 years), which aligns with previous reports, albeit with a shorter follow-up period (48 weeks). Across four clinical trials administering MSCs to 35 patients with psoriasis, no serious adverse events were reported (, , , ). Similarly, a systematic review concluded that MSC-based therapies are generally safe and may offer clinical benefits in psoriasis management (, ). Of interest, Patient 1 had a flare of psoriasis 27–31 weeks after the cessation of UC-MSC therapy, which could reflect disease rebound; however, the underlying mechanism remains unclear and warrants further investigation.
Regarding efficacy, observations from the three patients indicate that UC-MSCs provide clinical benefits, even in cases of severe and biologic-refractory psoriasis. Indeed, the contrast in treatment durations of previous biologics (years) vs. UC-MSCs (1 week) (Figures 1-3) highlights both the chronicity of prior biologic exposure and the need for new approaches in refractory cases. Previous clinical trials using UC-MSCs reported that up to 75% of patients achieved PASI75 at 24 – 48 weeks (, ), albeit with more intensive dosing schedules than ours. Additionally, MSCs from other sources (e.g., bone marrow) have shown efficacy in atopic dermatitis at lower doses (). Indeed, one of the key challenges with MSC therapy remains the lack of standardized dosing (), which requires further investigation through larger randomized controlled clinical trials.
An intriguing aspect of our findings is the enhanced responsiveness to previously ineffective or failed biologic therapies following UC-MSC treatment in Patients 2 and 3. While reloading with guselkumab and bimekizumab in Patients 2 and 3, respectively, may have contributed to the observed efficacy, the extent and durability of the response, particularly in the context of prior secondary failure, suggest the possibility that UC-MSC therapy may have also contributed to restoring responsiveness to biologics. This observation may be attributed to the ability of MSCs to reset the immune response, reducing chronic inflammation and restoring sensitivity to biologic agents (, ). By modulating the immune milieu, MSCs may diminish the pathogenic T-cell populations and cytokine levels that contribute to biologic resistance (, , ). Consequently, reintroducing biologics in a less inflammatory environment could enhance their efficacy, as observed in our patients.
A relevant finding related to this intriguing observation of a renewed response to a previously failed biologic treatment is the IMMhance study (). In this phase 3 randomized trial, the majority of patients with psoriasis who relapsed after withdrawal of risankizumab regained a response upon re-treatment, particularly when reloading doses were applied. However, a key distinction between the IMMhance study and our patients is that IMMhance evaluated planned withdrawal at W28 and re-treatment in patients who responded to risankizumab, while our patients experienced secondary biologic failure. Indeed, secondary biologic failure is rarely reversible by reintroduction of the same failed biologic. Furthermore, the timing and magnitude of the response observed after UC-MSC therapy, particularly the sustained benefit (absolute PASI <2) lasting over 2 years following biologic reinitiation, suggest that a broader immunological reset may have occurred. Given the emerging evidence of MSCs enhancing immune tolerance and reducing inflammatory load (, , ), we propose that UC-MSC therapy may have created a more permissive immunological environment, enabling guselkumab to regain efficacy.
At a cellular level, deep immunophenotyping revealed distinct baseline immune profiles corresponding to clinical phenotypes, with Patients 1 and 3 displaying a Th17-predominant profile (elevated IL - 17A-producing CD4+ and CD8+ T cells), which is associated with large-plaque psoriasis, while Patient 2 exhibited a T1-predominant profile (increased IFN-γ-producing T cells), which is linked to her small-plaque, follicular phenotype. Similarly, differences in other immune cell populations were also observed among the three patients (Supplementary Table 4): higher frequencies of IL - 17A- and IL - 22-producing skin-recirculating CD4+ and CD8+ T cells, B cells, and cDC1 were noted in Patients 1 and 3 compared to Patient 2; higher frequencies of IFN-γ-producing CD4+ T cells and Mucosal-Associated Invariant T (MAIT) cells, along with IFN-γ-producing skin-recirculating and skin-homing CD4+ and CD8+ T cells were found in Patient 2 compared to Patients 1 and 3. These differences may explain the varying responses observed with UC-MSC therapy. We also observed that the best clinical response to MSCs correlated with the highest host cytotoxic killing capacity, with Patient 2 (30% ApoMSCs) showing the most dramatic improvement out of the three patients, indicating its potential as a predictive biomarker for MSC responsiveness.
Additionally, we noted that UC-MSCs modulated lymphoid and myeloid cell populations in peripheral blood, which closely coincided with clinical improvement. Our findings indicate that UC-MSC treatment, either alone or as an adjunct to biologic therapy, may inhibit the migration of skin-homing T cells into involved skin in psoriasis, while facilitating the egress of CLA+CD103+ cells (, ) into the peripheral circulation. This observation is consistent with prior findings showing a significant decrease in CD103+ T cells in psoriasis-involved skin following treatment with IL - 17A or IL - 23p19 inhibitors (, ), suggesting that MSCs may exert similar effects on T-cell migration dynamics (, , ). Furthermore, phenotypic shifts in monocyte subsets were observed with a reduction in the frequency of CD14+CD16+ intermediate monocytes correlating with decreased PASI values across all patients. Given that lower frequencies of intermediate monocytes are associated with milder disease in patients with psoriasis (), this supports the notion that non-classical monocytes exhibit anti-inflammatory properties (), reinforcing a reduction in inflammatory status.
The immunomodulatory properties of MSCs are probably central to their therapeutic effects in psoriasis. MSCs can modulate both innate and adaptive immune responses by secreting anti-inflammatory cytokines and promoting the development of regulatory immune cells (, , ). For instance, MSCs have been shown to inhibit T helper (Th) 17 cell proliferation and reduce the production of pro-inflammatory cytokines such as IL - 17 and TNF-α, which play a pivotal role in psoriasis pathogenesis (–). Additionally, MSCs can enhance Treg function, restoring immune homeostasis (–). In our study, we observed an increase in Treg frequencies following UC-MSC therapy, correlating with clinical improvement. This aligns with previous findings indicating that MSC-induced Treg expansion contributes to therapeutic efficacy in inflammatory diseases (, , , , ). Given the role of Tregs in maintaining immune homeostasis and controlling inflammation, modulating their frequency and function may be a key mechanism by which MSCs can reset the recipient’s immune response, enhancing outcomes with previously failed biologics (–, ). Similar studies of MSCs in psoriasis have reported increased frequencies of Tregs and CD4+ and CD8+ central memory T cells alongside a decrease in circulating Th17 and CD4+ naïve T cells. Furthermore, co-culturing of psoriasis patient PBMCs with UC-MSCs significantly inhibited inflammatory cytokine production (IFN-γ, TNF, and IL - 17A) compared to controls (), reinforcing the immunomodulatory properties of MSCs.
In addition to direct immunomodulation, MSCs may also influence the skin microenvironment by affecting keratinocyte behavior and angiogenesis (, , , ). MSCs secrete anti-inflammatory cytokines and perhaps other factors that inhibit keratinocyte proliferation and promote differentiation, thereby normalizing the aberrant epidermal turnover characteristic of psoriasis plaques (). Moreover, MSC-derived exosomes have been shown to alleviate psoriasis-like skin inflammation in a mouse model by modulating the IL - 23/IL-17 axis and inhibiting dendritic cell activation, promoting the resolution of psoriasis (, ). In an imiquimod-induced psoriasiform model, human UC-MSC-derived exosomes significantly reduced epidermal proliferation, PASI, and the expression of IL - 17, IL - 23, and CCL20 while inhibiting STAT3 phosphorylation ().
In addition to regulating the skin microenvironment, MSCs are known to inhibit neutrophil activity and plasmacytoid dendritic cell (pDC)-driven type I IFN responses, disrupting feedback loops that perpetuate inflammation in psoriasis (). This is mediated in part by MSC-derived soluble factors such as TGF-β, IL - 10, PGE2, indoleamine 2,3-dioxygenase (IDO), and tumor necrosis factor-stimulated gene-6 (TSG - 6), along with extracellular vesicles (exosomes) that exert systemic and local anti-inflammatory effects (–). In imiquimod mouse models treated with UC-MSCs primed by IFN-γ and TNF-α, TSG - 6 was shown to inhibit neutrophil recruitment by decreasing the expression of CXCL1 with a subsequent reduced level of STAT1 phosphorylation in keratinocytes (–).
Collectively, our findings support the view that UC-MSCs exert their therapeutic effect on psoriasis via layered immunological and tissue-level mechanisms: suppression of pathogenic T-cell subsets; expansion of Tregs; modulation of cytokine and chemokine networks; inhibition of dendritic cell activity; and regulation of monocyte subsets, keratinocyte behavior, and the overall inflammatory burden. Our case series contributes to this growing body of evidence and highlights the need for controlled studies to further define these mechanisms and identify predictive biomarkers of response.
Limitations of this case series include the small sample size that limited statistical analysis in immunological profiling data, variations in previous treatments, timelines of clinical assessments and immuno-phenotyping, and potential confounders such as short courses of topical corticosteroids during psoriasis flare-ups post-MSC therapy. In Patient 1, the concurrent use of an etanercept biosimilar along with UC-MSCs represents a further confounding factor in the interpretation of the clinical response. Moreover, the duration of UC-MSC therapy was limited owing to the constraints of compassionate-use access, which provided only 2–3 × 106 cells/kg, two infusions per patient, 1 week apart. Nonetheless, the depth of immune profiling and long-term follow-up strengthen our findings.
In conclusion, our study contributes to the growing body of evidence supporting the safety and potential efficacy of MSC therapy for severe, and in particular, biologic-refractory psoriasis. The observed clinical improvements and novel durable enhanced responsiveness to previously failed biologics underscore the promise of MSCs as a therapeutic strategy. Undoubtedly, several challenges remain, including the optimal tissue source (), dosing regimen (), mechanisms of action (–), predictive biomarkers of treatment response, and long-term safety and efficacy. Further investigations of randomized controlled trials with larger sample sizes, perhaps in patients with psoriasis at an earlier stage in their therapeutic journey, are warranted to elucidate the mechanisms of action and therapeutic potential of MSCs in the management of psoriasis.
Statements
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.
Ethics statement
The studies involving humans were approved by the BSTOP Ethics Committee (REC 11/HO802/7; IRAS 71048), enabling patient consent and immune phenotyping. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article. Written informed consent was obtained from the participant/patient(s) for the publication of this case report.
Author contributions
SL: Writing – original draft, Methodology, Data curation, Software, Supervision, Formal analysis, Visualization, Investigation, Validation, Funding acquisition, Resources, Writing – review & editing, Conceptualization, Project administration. SS: Visualization, Formal analysis, Validation, Data curation, Project administration, Methodology, Software, Writing – review & editing, Writing – original draft. CS: Methodology, Data curation, Investigation, Software, Visualization, Validation, Writing – review & editing, Formal analysis. CG: Data curation, Investigation, Methodology, Visualization, Software, Validation, Writing – review & editing, Formal analysis. SA: Data curation, Investigation, Validation, Writing – review & editing, Formal analysis. IT: Validation, Investigation, Writing – review & editing, Formal analysis, Data curation. AA: Data curation, Writing – review & editing, Investigation, Visualization, Writing – review & editing, Data curation, Investigation, Validation. ED: Writing – review & editing, Data curation, Resources, Investigation, Validation. HD: Formal analysis, Methodology, Validation, Data curation, Investigation, Software, Writing – review & editing. SW: Validation, Data curation, Resources, Formal analysis, Writing – review & editing, Project administration. JM: Visualization, Resources, Validation, Writing – review & editing, Methodology, Supervision, Investigation. GL: Data curation, Methodology, Investigation, Supervision, Visualization, Writing – review & editing, Validation, Formal analysis, Resources. FD: Methodology, Investigation, Supervision, Data curation, Conceptualization, Resources, Writing – review & editing. PD: Data curation, Resources, Methodology, Writing – review & editing, Supervision, Investigation. CG: Data curation, Validation, Resources, Conceptualization, Project administration, Visualization, Methodology, Formal analysis, Writing – review & editing, Supervision, Funding acquisition, Investigation, Software.
Funding
The author(s) declare financial support was received for the research and/or publication of this article. The costs of the mesenchymal stromal cells were supported by an unrestricted medical grant from Almirall. Hannah Dawe is supported by the UK Medical Research Council (MR/W006820/1) and is a King’s College London member of the MRC Doctoral Training Partnership in Biomedical Sciences. This research was partially supported by the King’s Health Partners Centre for Translational Medicine. The views expressed are those of the author(s) and not necessarily those of King’s Health Partners.
Acknowledgments
We thank the three patients and their families, in addition to the dermatology, hematology, stem cell therapy, pharmacy, and biological safety teams at King’s College Hospital, London, for their support and provision of UC-MSCs. We are grateful to Dr. Shikha Gupta (Beckenham Beacon Hospital) for patient referral. We acknowledge Professor Catherine Smith (King’s College London) for the BSTOP ethical approval (REC 11/HO802/7; IRAS 71048), which enabled patient consent and immune phenotyping.
Conflict of interest
Disclosure of potential conflict of interest: SL has received honoraria, educational/travel grants and/or research support from Almirall, Amryt/Chiesi, Eli Lilly, Johnson & Johnson, Novartis, Takeda, and UCB. SA has received honoraria and/or travel grants from Johnson & Johnson, Eli Lilly, and Bristol-Myers Squibb. JM has received honoraria from Almirall, Chiesi, the Leo Foundation, ONO Pharmaceuticals, TWi Pharmaceuticals, and Yep Pharmaceuticals. GL is one of the founders of Quell Therapeutics. PM has received honoraria from Sanofi and Bristol Myers Squibb. CEMG has received honoraria and/or research support from AbbVie, Almirall, Amgen, Anaptysbio, Artax, Boots UK Ltd., Boehringer-Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly, Evelo Biosciences, Galderma, GSK, Inmagene, Johnson & Johnson, Kyowa Kirin, Novartis, ONO Pharmaceuticals, Rubedo, Sun Pharmaceuticals, and UCB.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that Generative AI was used in the creation of this manuscript. ChatGPT 4.0 was used to improve the readability of the manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Author disclaimer
The views expressed are those of the author(s) and not necessarily those of King’s Health Partners.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1656724/full#supplementary-material
Abbreviations
DLQI, Dermatology Life Quality Index; FoxP3, forkhead box protein PATIENT 3; IL, interleukin; MSC, mesenchymal stromal cells; PASI, Psoriasis Area Severity Index; PBMCs, peripheral blood mononuclear cells; TNF, tumor necrosis factor; Tregs, regulatory T cells.
References
1
GriffithsCEMArmstrongAWGudjonssonJEBarkerJNWN. Psoriasis. Lancet. (2021) 397:1301–5. doi: 10.1016/S0140-6736(20)32549-6
2
LwinSMAzrielantSHeJGriffithsCEM. Curing psoriasis. J Invest Dermatol. (2024) 144:2645–9. doi: 10.1016/j.jid.2024.09.012
3
MastorinoLRoccuzzoGDapavoPSiliquiniNAvalloneGRubattoMet al. Patients with psoriasis refractory to multiple biological therapies: characteristics and definition of a difficult-to-treat population. Br J Dermatol. (2022) 187:263–5. doi: 10.1111/bjd.21048
4
ViolaRMastorinoLMegnaMDamianiGGisondiPArgenzianoGet al. Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multi-center Italian cohort. Int J Dermatol. (2024) 63:351–8. doi: 10.1111/ijd.17005
5
LwinSMSnowdenJAGriffithsCEM. The promise and challenges of cell therapy for psoriasis. Br J Dermatol. (2021) 185:887–98. doi: 10.1111/bjd.20517
6
GiacominiCGraneliCHicksRDazziF. The critical role of apoptosis in mesenchymal stromal cell therapeutics and implications in homeostasis and normal tissue repair. Cell Mol Immunol. (2023) 20:570–82. doi: 10.1038/s41423-023-01018-9
7
YangJXiaoMMaKLiHRanMYangSet al. Therapeutic effects of mesenchymal stem cells and their derivatives in common skin inflammatory diseases: atopic dermatitis and psoriasis. Front Immunol. (2023) 14:1092668. doi: 10.3389/fimmu.2023.1092668
8
Ramirez GaleraMSvalgaardJWoetmannA. Therapeutic potential of adipose derived stromal cells for major skin inflammatory diseases. Front Med (Lausanne). (2024) 11:1298229. doi: 10.3389/fmed.2024.1298229
9
ChenHNiuJ-WNingH-MPanXLiX-BLiYet al. Treatment of psoriasis with mesenchymal stem cells. Am J Med. (2016) 129:e13–4. doi: 10.1016/j.amjmed.2015.11.001
10
De JesusMMSantiagoJSTrinidadCVSeeMESemonKRFernandezMOJr.et al. Autologous adipose-derived mesenchymal stromal cells for the treatment of psoriasis vulgaris and psoriatic arthritis: a case report. Cell Transpl. (2016) 25:2063–9. doi: 10.3727/096368916X691998
11
ChenMPengJXieQXiaoNSuXMeiHet al. Mesenchymal stem cells alleviate moderate-to-severe psoriasis by reducing the production of type I interferon (IFN-I) by plasmacytoid dendritic cells (pDCs). Stem Cells Int. (2019) 2019:6961052. doi: 10.1155/2019/6961052
12
WangSGHsuNCWangSMWangFN. Successful treatment of plaque psoriasis with allogeneic gingival mesenchymal stem cells: a case study. Case Rep Dermatol Med. (2020) 2020:4617520. doi: 10.1155/2020/4617520
13
DiotalleviFDi VincenzoMMartinaERadiGLaricciaVOffidaniAet al. Mesenchymal stem cells and psoriasis: systematic review. Int J Mol Sci. (2022) 23:15080. doi: 10.3390/ijms232315080
14
ChenY-KMohamedAHAlsaiariAABokovDOPatelAAAl AbdulmonemWet al. The role of mesenchymal stem cells in the treatment and pathogenesis of psoriasis. Cytokine. (2024) 182:156699. doi: 10.1016/j.cyto.2024.156699
15
GalleuARiffo-VasquezYTrentoCLomasCDolcettiLCheungTSet al. Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation. Sci Transl Med. (2017) 9:eaam7828. doi: 10.1126/scitranslmed.aam7828
16
CheungTSGiacominiCCeredaMAvivar-ValderasACapeceDBertolinoGMet al. Apoptosis in mesenchymal stromal cells activates an immunosuppressive secretome predicting clinical response in Crohn’s disease. Mol Ther. (2023) 31:3531–3544. doi: 10.1016/j.ymthe.2023.10.004
17
KlicznikMMMorawskiPAHollbacherBVarkhandeSRMotleySJKuri-CervantesLet al. Human CD4+CD103+ cutaneous resident memory T cells are found in the circulation of healthy individuals. Sci Immunol. (2019) 4:eaav8995. doi: 10.1126/sciimmunol.aav8995
18
FarreraCMelchiottiRPetrovNTengKWWWongMTLohCYet al. T cell phenotyping uncovers systemic features of atopic dermatitis and psoriasis. J Allergy Clin Immunol. (2020) 145:1021–5. doi: 10.1016/j.jaci.2019.11.030
19
BajouriADayaniDSharghiATKarimiSNiknezhadiMBidgoliKMet al. Subcutaneous injection of allogeneic adipose-derived mesenchymal stromal cells in psoriasis plaques: clinical trial phase I. Cell J. (2023) 25:363–71. doi: 10.22074/cellj.2023.1973793.1167
20
ChengLWangSPengCZouXYangCMeiHet al. Human umbilical cord mesenchymal stem cells for psoriasis: a phase 1/2a, single-arm study. Sig Transduct Tar Ther. (2022) 7:263. doi: 10.1038/s41392-022-01059-y
21
MeybodiMAMNilforoushzadehMAKhandanDezfullyNMansouriP. The safety and efficacy of adipose tissue-derived exosomes in treating mild to moderate plaque psoriasis. Life Sci. (2024) 353:122915. doi: 10.1016/j.lfs.2024.122915
22
YaoDYeSHeZHuangYDengJWenZet al. Adipose-derived mesenchymal stem cells (AD-MSCs) in the treatment for psoriasis: results of a single-arm pilot trial. Ann Transl Med. (2021) 9:1653. doi: 10.21037/atm-21-5028
23
WangZYifanHWangXChenYWuDJiHet al. Comparative analysis of the therapeutic effects of fresh and cryopreserved human umbilical cord derived mesenchymal stem cells in the treatment of psoriasis. Stem Cell Rev Rep. (2023) 19:1922–36. doi: 10.1007/s12015-023-10556-8
24
DeyRDasA. Efficacy of mesenchymal stem cell transplantation therapy to mitigate psoriasis: A systematic review and meta-analysis. Curr Res Transl Med. (2025) 73:103504. doi: 10.1016/j.retram.2025.103504
25
SeoH-MLewB-LLeeYWSongSWParkCOParkYLet al. Phase 1/2 trials of human bone marrow-derived clonal mesenchymal stem cells for treatment of adults with moderate to severe atopic dermatitis. J Allergy Clin Immunol. (2024) 154:965–73. doi: 10.1016/j.jaci.2024.06.013
26
Del PapaBSportolettiPCecchiniDRosatiEBalucaniCBaldoniSet al. Notch1 modulates mesenchymal stem cells mediated regulatory T cell induction. Eur J Immunol. (2013) 43:182–7. doi: 10.1002/eji.201242643
27
NegiNGriffinMD. Effects of mesenchymal stromal cells on regulatory T cells: current understanding and clinical relevance. Stem Cells. (2020) 38:596–605. doi: 10.1002/stem.3151
28
BlauveltALeonardiCLGooderhamMPappKAPhilippSWuJJet al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasisA phase 3 randomized clinical trial (IMMhance). JAMA Dermatol. (2020) 156:649–58. doi: 10.1001/jamadermatol.2020.0723
29
Owczarczyk-SaczonekAKasprowicz-FurmańczykMCzerwińskaJKrajewska-WłodarczykMPlacekW. The effect of therapy on TRM in psoriatic lesions. Postepy Dermatol Alergol. (2022) 39:209–20. doi: 10.5114/ada.2021.113125
30
KruegerJLangleyRGNigenSKasparekTDi ComiteGOrtmannCEet al. Secukinumab versus guselkumab in the complete resolution of Ustekinumab-resistant psoriatic plauques: The ARROW study. Exp Dermatol. (2023) 19:1834–47. doi: 10.1111/exd.14828
31
LiuGWangZLiS. Heterogeneity and plasticity of tissue-resident memory T cells in skin diseases and homeostasis: a review. Front Immunol. (2024) 15:1378359. doi: 10.3389/fimmu.2024.1378359
32
DashtiMMohammadiMDehnaviSSadeghiM. Immunomodulatory interactions between mesenchymal stromal/stem cells and immune cells in psoriasis: therapeutic potential and challenges. Stem Cell Res Ther. (2025) 16:241. doi: 10.1186/s13287-025-04375-6
33
GoldenJBGroftSGSqueriMVDebanneSMWardNLMcCormickTSet al. Chronic psoriasis skin inflammation leads to increased monocyte adhesion and aggregation. J Immunol (Baltimore Md.:1950). (2015) 195:2006–15. doi: 10.4049/jimmunol.1402307
34
NarasimhanPBMarcovecchioPHamersAAJHedrickCC. Nonclassical monocytes in health and disease. Ann Rev Immunol. (2019) 37:439–56. doi: 10.1146/annurev-immunol-042617-053119
35
GhannamSPeneJTorcy-MoquetGJorgensenYsselH. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol. (2010) 185:302–12. doi: 10.4049/jimmunol.0902007
36
RozenbergARezkABoivinM-NDarlingtonPJNyirendaMLiRet al. Human mesenchymal stem cells impact Th17 and Th1 responses through a prostaglandin E2 and myeloid-dependent mechanism. Stem Cells Transl Med. (2016) 5:1506–14. doi: 10.5966/sctm.2015-0243
37
DairovASekenovaAAlimbekSNurkinaAShakhatbayevMKumashevaVet al. Psoriasis: the versatility of mesenchymal stem cell and exosome therapies. Biomolecules. (2024) 14:1351. doi: 10.3390/biom14111351
38
RenXZhongWLiWTangMZhangKZhouFet al. Human umbilical cord mesenchymal stem cells alleviate psoriasis through TNF-α/NF-κB/MMP13 pathway. Inflammation. (2023) 46:987–1001. doi: 10.1007/s10753-023-01785-7
39
ZhangYYanJLiZZhengJSunQ. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate psoriasis-like skin inflammation. J Interferon Cytokine Res. (2022) 42:8–18. doi: 10.1089/jir.2021.0146
40
TanYLAl-MasawaMEEngSPShafieeMNLawJXNgMH. Therapeutic efficacy of interferon-gamma and hypoxia-primed mesenchymal stromal cells and their extracellular vesicles: underlying mechanisms and potentials in clinical translation. Biomedicines. (2024) 12:1369. doi: 10.3390/biomedicines12061369
41
DingYGongPJiangJFengCLiYSuXet al. Mesenchymal stem/stromal cells primed by inflammatory cytokines alleviate psoriasis-like inflammation via the TSG - 6-neutrophil axis. Cell Death Dis. (2022) 13:996. doi: 10.1038/s41419-022-05445-w
42
DunnCMKameishiSChoY-KSongSUGraingerDWOkanoT. Interferon-gamma primed human clonal mesenchymal stromal cell sheets exhibit enhanced immunosuppressive function. Cells. (2022) 11:3738. doi: 10.3390/cells11233738
43
RibeiroALaranjeiraPMendesSVeladaILeiteCAndradePet al. Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells. Stem Cell Res Ther. (2013) 4:125. doi: 10.1186/scrt336
44
ShinT-HKimH-SChoiSWKangK-S. Mesenchymal stem cell therapy for inflammatory skin diseases: clinical potential and mode of action. Int J Mol Sci. (2017) 18:244. doi: 10.3390/ijms18020244
45
HoseinzadehAEsmaeiliS-ASahebiRMelakAMMahmoudiMHasanniaMet al. Fate and long-lasting therapeutic effects of mesenchymal stromal/stem-like cells: mechanistic insights. Stem Cell Res Ther. (2025) 16:33. doi: 10.1186/s13287-025-04158-z
46
PaganelliATarentiniEBenassiLKaleciSMagnoniC. Mesenchymal stem cells for the treatment of psoriasis: a comprehensive review. Clin Exp Dermatol. (2020) 45:824–30. doi: 10.1111/ced.14269
Summary
Keywords
psoriasis, multiple biologic-refractory, mesenchymal stromal cells, immunomodulatory, regulatory T cells, monocytes
Citation
Lwin SM, Solanky S, Scottà C, Giacomini C, Azrielant S, Tosi I, Al-Haddabi A, Duarte-Williamson E, Dawe H, Walsh S, McGrath JA, Lombardi G, Dazzi F, Di Meglio P and Griffiths CEM (2025) Mesenchymal stromal cells as rescue therapy in biologic-refractory psoriasis: insights from a case series. Front. Immunol. 16:1656724. doi: 10.3389/fimmu.2025.1656724
Received
30 June 2025
Accepted
11 August 2025
Published
03 September 2025
Volume
16 - 2025
Edited by
Varun Sasidharan Nair, Italian Institute of Technology (IIT), Italy
Reviewed by
Špela Konjar, Blood Transfusion Centre of Slovenia, Slovenia
Lijie Zhang, Capital Medical University, China
Krisztian Nemeth, Semmelweis University, Hungary
Updates
Copyright
© 2025 Lwin, Solanky, Scottà, Giacomini, Azrielant, Tosi, Al-Haddabi, Duarte-Williamson, Dawe, Walsh, McGrath, Lombardi, Dazzi, Di Meglio and Griffiths.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Christopher E. M. Griffiths, Chris.griffiths@kcl.ac.uk
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.